Rossi et al. examined FASN expression levels in primary prostate cancers from 64 patients and found that FASN expression was strong in 8%, moderate in 30%, and weak in 53%, with 9% showing no expression [6]. This evidence concerns the gene FASN and Familial prostate cancer.